Celularity Inc
For the period ended Dec 31, 2023. Filed Jul 30, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Jul 30, 2024
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flow
CONSOLIDATED STATEM ENTS OF CASH FLOWS
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flow from operating activities: | ||
| Net (loss) income | $(196,295) | $14,192 |
| Adjustments to reconcile net (loss) income to net cash used in operations: | ||
| Depreciation and amortization | 9,324 | 9,436 |
| Non cash lease expense | (13) | (59) |
| Deferred income taxes | — | (1) |
| Provision for doubtful accounts | 1,233 | 1,877 |
| Provision for inventory obsolescence | 1,328 | — |
| Change in fair value of warrant liabilities | (6,164) | (42,109) |
| Inventory impairment | 5,384 | 904 |
| Goodwill impairment | 112,347 | 3,610 |
| IPR&D impairment | 107,800 | — |
| Stock-based compensation expense | 15,017 | 15,856 |
| Change in fair value of contingent consideration | (104,339) | (126,277) |
| Acquired in-process research and development | 3,000 | — |
| Issuance of common stock for stem-cells to be used in research and development | 1,000 | — |
| Issuance of common stock relating to Yorkville debt extension | 712 | — |
| Discounts arising from RWI loan arrangement - related party | 2,151 | — |
| Fair value of warrant modification for professional services | 403 | — |
| Change in fair value of debt | 1,177 | 2,522 |
| Change in fair value of contingent stock consideration | (159) | 186 |
| Other, net | 4,157 | (37) |
| Changes in assets and liabilities: | ||
| Accounts receivable | (6,827) | (3,584) |
| Inventory | (865) | (16,891) |
| Prepaid expenses and other assets | 5,606 | 49 |
| Accounts payable | 8,497 | (2,948) |
| Accrued expenses and other liabilities | (1,128) | (2,623) |
| Accrued R&D software | (3,834) | 7,333 |
| Right-of-use assets and lease liabilities | 275 | 263 |
| Deferred revenue | 1,528 | 425 |
| Net cash used in operating activities | (38,685) | (137,876) |
| Cash flow from investing activities: | ||
| Capital expenditures | (1,048) | (5,236) |
| Purchase of acquired in-process research and development | (3,000) | — |
| Net cash used in investing activities | (4,048) | (5,236) |
| Cash flow from financing activities: | ||
| Proceeds from RWI senior secured bridge loan and warrants - related party | 12,375 | 46,491 |
| Principal payments of Yorkville short-term debt | (16,811) | — |
| Proceeds from issuance of senior secured C.V. Starr bridge loan and warrants - related party | 4,994 | — |
| Proceeds from short-term debt | — | 39,200 |
| Proceeds from the sale of common stock in ATM offering | 136 | 6,519 |
| Payments of ATM offering costs and commissions | — | (498) |
| Proceeds from other short-term debt | 2,000 | — |
| Proceeds from other short-term debt - related party | 1,000 | — |
| Proceeds from PIPE financing | 12,750 | 30,000 |
| Proceeds from the exercise of stock options | 304 | 862 |
| Tax withholding on vesting of restricted stock units | (101) | (132) |
| Proceeds from registered direct offerings | 9,000 | — |
| Payments of PIPE and other issuance costs | (1,553) | (2,604) |
| Net cash provided by financing activities | 24,094 | 119,838 |
| Net decrease in cash, cash equivalents and restricted cash | (18,639) | (23,274) |
| Cash, cash equivalents and restricted cash at beginning of year | 28,802 | 52,076 |
| Cash, cash equivalents and restricted cash at end of year | $10,163 | $28,802 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $1,073 | $— |
| Supplemental non-cash investing and financing activities: | ||
| Property and equipment included in accounts payable and accrued expenses | $(223) | $(683) |
| Common stock issued for short-term debt conversion | $4,599 | $4,099 |
| Issuance of warrants on senior secured bridge loans | $2,002 | $— |
| Reduction of right-of-use assets and associated lease liability due to lease modification | $(2,083) | $— |
| PIPE related costs included in accrued expenses | $(69) | $— |
| Interest accrued on senior secured loans within long-term debt - related parties | $(1,770) | $— |
| Reclassification of option liabilities to equity | $— | $441 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.